Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases.

CTP-692

A promising first-in-class approach to broaden the scope of treating schizophrenia

CTP-543

A drug candidate for alopecia areata, a disease with no currently-approved treatments

LATEST NEWS

Apr 01, 2020
Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

Feb 27, 2020
Concert Pharmaceuticals Reports 2019 Financial Results and Provides Update on Clinical Programs

© 2020 Concert Pharmaceuticals. All rights reserved.
HOME | SITEMAP | CONTACT | TERMS OF USE | PRIVACY POLICY
Back to Top